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1918 H1N1 DRIFT DNA VACCINE
S T A T E N S 
S E R U M 
I N S T I T U T
1 2 2 1 1K. Bragstad , C. Martel , B. Aasted , L.P. Nielsen  and A. Fomsgaard
1 Department of Virology, Statens Serum Institute, Copenhagen, Denmark
2 Department of Veterinary Pathobiology, Faculty of Life Sciences,University of Copenhagen, Denmark
Influenza vaccines with the ability to induce immune responses cross-reacting with drifted virus variants would be of great advantage 
for vaccine development against seasonal and emerging new strains. We demonstrate that gene gun administrated DNA vaccine 
encoding HA and NA and/or NP and M proteins of the H1N1 pandemic virus from 1918 induce protection in ferrets against infection 
with a H1N1 (A/New Caledonia/20/99(H1N1)) virus which was included in the conventional vaccine for the 2006-2007 season. The 
viruses are separated by a time interval of 89 years and differ by 21.2% in the HA1 protein. These results suggest not only a unique 
ability of the DNA vaccines, but perhaps also natural infection, to induce cross-protective responses against even extremely drifted 
virus variants.
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Virus titre in nasal wash post challenge
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Virus titre in nasal wash day 7 pc
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IFNy production in total lymphocytes
PMA stimulation Day 7 post challenge
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Influenza specific IgG in sera
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INTRODUCTION
DNA vaccines induce an immune 
response which is comparable to the 
response acquired by natural virus 
infection by activating both humoral 
and cell-mediated immunity 
We wanted to assess the induced 
immune response and level of cross-
protection by ferrets vaccinated with a 
H1N1 DNA vaccine based on the 
pandemic "Spanih flu" virus from 1918 
and challenged with a contemporary 
H1N1 virus A New Caledonia
 
/ /20/99 
(NC)
RESULTS
Clinical symptoms
lUnvaccinated ferrets had a higher rise in body 
temperature at day two (the day of maximum 
temperature rise) after infection with A/New 
Caledonia/20/99(H1N1) than did the HA/NA 1918 
DNA vaccinated ferrets (P=0.2). 
lNo difference in body weight at day four (the day for 
maximal body weight loss) between the two groups 
was observed 
Reduction in virus load
lDNA vaccinated groups had a reduction in virus titre during infection 
not seen in the conventional vaccine or the empty plasmid group. 
lThe H/N 1918 DNA vaccinated group had a significant (P<0.05) 
reduction in virus titre from day four to day five (Figure 1). 
l The H/N NC DNA vaccine was the most effective vaccine in preventing 
infection and virus clearance. 
l Only three of five ferrets in the 1918 DNA vaccinated group had 
detectable virus load at day seven compared to all animals in the naïve 
group.
lNotably, also the ferrets vaccinated with NP and M DNA had a better 
virus clearance than the control groups. 
Reduction in IFNy-production
IFN-y positive lymphocytes were estimated by flow cytometry as a 
measure of virus infection.
l A higher percentage of the total lymphocytes produce IFN-y at day 
seven after infection with A/New Caledonia/20/99(H1N1) in the 
negative control group and the conventional vaccine group compared to 
the DNA vaccinated groups, indicating an ongoing or recent infection. 
l There are significantly less IFN-y produced day seven in the H/N 1918 
H1N1 DNA vaccine group compared to the negative control group 
(P<0.05)
Influenza specific antibody response after DNA vaccination
lA significant higher influenza A IgG titer (P<0.05) compared to the 
negative control group was observed at the day of challenge for the H/N 
1918 DNA vaccinated ferrets, indicating induction of influenza specific 
antibodies after DNA vaccination.  
lAt day five post infection, both H/N DNA vaccinated animals and 
conventional vaccine vaccinated animals showed vaccine induced 
influenza specific antibodies. 
lThe H/N 1918 DNA and the conventional vaccine vaccinated animals 
had comparable recall antibody titre at day seven post infection 
Induction of HA inhibiting  antibodies after DNA vaccination
lFerrets vaccinated with the H/N NC H1N1 DNA vaccine had significant HI 
titre against the A/New Caledonia/20/99(H1N1) virus after DNA 
vaccination at the day of challenge.
lThe H/N NC DNA vaccine gave a better recall response of inhibitory 
antibodies than the conventional trivalent protein vaccine.
l At day five after infection 60% of the H/N NC  H1N1 DNA vaccinated 
ferrets had seroconverted (HI>40), compared to 40% of the ferrets in the 
conventional vaccine group. Also a >2.5 fold increase in HI MGT was 
accomplished after vaccination measured the day of challenge. 
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CONCLUSIONS
nHA+NA DNA vaccine based on the pandemic 1918 
H1N1 virus induce specific IgG antibodies against 
A/New Caledonia/20/99(H1N1) (ELISA), comparable to  
titers induced by the conventional vaccine. However, 
only H+N NC DNA vaccine induced HA inhibitory 
antibodies (HI assay).
nThe HA+NA H1N1 1918 DNA vaccinated ferrets  
cleared the virus infection better than the conventional 
vaccine.
 
nFerrets, vaccinated with DNA vaccine, which cleared 
their infection early, also had a low percentage of IFN-y 
positive lymphocytes upon unspecific antigen 
stimulation. Animals in the conventional vaccine group 
and negative control group, with an ongoing infection, 
still had active IFN-y positive inflammatory cells at day 
seven,  as a sign of infection. 
DNA vaccines might be better candidates for influenza 
prophylaxis than annual conventional protein based 
vaccines which frequently need to be updated to match 
the circulating influenza virus. DNA vaccination induces 
broader cross-reactivity against drifted strains and longer 
memory responses. 
METHODS
Construction of the DNA vaccine
The 1918 pandemic H1N1 genes were designed from nucleotide sequences of  A/South 
Carolina/1/18 and A/Brevig Mission/1/18 published in GenBank. A/New Caledonia/20/99 virus 
was sequenced in-house. The genes were codon optimised and made synthetically by GeneArt.
Immunisations
A total of 25 ferrets (Mustela Putorius Furo), approximately seven months old,  were divided in 
five animals per group by a chip-tag for cats (E-vet, pet-id, Haderslev, Denmark). 
Five groups of five animals were vaccinated as follows: (1) HA and NA 1918 H1N1 DNA 
vaccinated, (2) HA and NA A/New Caledonia/20/99(H1N1) DNA vaccinated, (3) NP and M 1918 
H1N1 DNA vaccinated, (4) conventional trivalent protein vaccine 2006-07 (incl. A/New 
Caledonia/20/99)(Influvac, Solvay Pharmaceuticals), (5) empty plasmid vaccinated (negative 
vaccine control).
The ferrets were gene gun (Helios, Bio-Rad, Hercules, CA) inoculated (400 psi compressed 
helium) on shaved abdominal skin, using 2 µg plasmid DNA-coated gold particles (1.6 µm-sized 
particles), 80-95% coating efficiency each shot. Each ferret received two shots, three times, two 
weeks apart. Ferrets were challenged ten days after third immunisation by 5.5x10E5 50% tissue 
culture infectious dose (TCID50) of A/New Caledonia/20/99(H1N1) administrated into the 
nostrils with a syringe. 
Quantitative real time RT-PCR assay for influenza A. 
Nostrils of each ferret were flushed with 1 ml PBS and the flushings were frozen down 
immediately for real-time RT-PCR analysis. 
Serum antibody determined by ELISA
ELISA plates (96 wells) were coated with 100 µl, split influenza vaccine 2006/07 (Including 
A/New Caledonia/20/99(H1N1))(Vaxigrip, Sanofi Pasteur, Belgium) diluted 1:100 in 35 mM 
NaHCO3 pH 9.6 and 15 mM Na2CO3 over night at 4°C. 
Intracellular staining for FACS analyses of gamma-interferon levels
Blood was drawn in heparinised tubes. The Peripheral Blood Leucocytes were stimulated with 
phorbol-12-myristate-13-acetate (PMA, Sigma) to a final concentration of 20 ng/ml together for 4 
hours with Brefeldin A (Sigma; St. Louis, USA) to a final concentration of 10 µg/ml culture and 
Ionomycin (Sigma) to a final concentration of 1 µg/ml. The primary antibody was 500 ng of a 
cross-reactive mouse monoclonal antibody to bovine gamma-interferon (Serotec). Incubation 
was one hour in 4°C.  0.5 µl FITC-conjugated rabbit anti-mouse was applied as secondary 
antibody (Dako)and the cells were incubated again for one hour at 4°C.
Haemagglutination inhibition (HI)
Performed after WHO recommendations with A/New Caledonia/20/99(H1N1) virus 
standardised to 8 HAU.
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